<DOC>
	<DOCNO>NCT02044250</DOCNO>
	<brief_summary>Objectives : To compare efficacy safety clopidogrel monotherapy aspirin monotherapy patient receive dual triple antiplatelet therapy 1 year ( ± 6 month ) drug-eluting stent implantation coronary artery disease Patient Enrollment : 5530 patient enrol 55 center Korea Patient Follow-up : Clinical follow-up occur 1 , 12 24 month . Primary Endpoint : Composite endpoint MACE major bleed Secondary Endpoint : Device-oriented composite outcome include TLR ( target lesion revascularization ) , TVR ( target vessel revascularization ) , stent thrombosis , minor GI ( gastrointestinal ) complication</brief_summary>
	<brief_title>Harmonizing Optimal Strategy Treatment Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy ( HOST-EXAM )</brief_title>
	<detailed_description>The primary purpose study compare efficacy safety antiplatelet monotherapy aspirin clopidogrel 2 year patient experience MACE ( major adverse cardiac event ) include all-cause death , acute coronary syndrome include non-fatal MI ( myocardial infarction ) , urgent revascularization combine antiplatelet therapy 12 ± 6 month PCI ( percutaneous coronary intervention ) DES ( drug-eluting stent ) . The trial test hypothesis clopidogrel superior aspirin prevent clinical event device-oriented outcome . Clinical event define composite all-cause death , non-fatal MI , stroke , readmission due acute coronary syndrome ( ACS ) , Bleeding Academic Research Consortium ( BARC ) class ≥ 3.29 Device-oriented outcome include target lesion/vessel revascularization ( TLR/TVR ) Academic Research Consortium ( ARC ) -defined stent thrombosis . The primary endpoint study rate clinical event define composite MACE major bleed complication . MACE include all-cause death , non-fatal MI , stroke , readmission due ACS ( acute coronary syndrome ) . Major bleeding define bleeding ( BARC class ≥ 3 ) 24 month . Non-fatal MI define confirmed evidence myocardial necrosis clinical setting consistent myocardial ischemia without result death , support electrocardiography , cardiac enzyme , cardiac image accord third Universal Definition MI.37 , 38 A readmission due ACS define re-hospitalization definitely originate ACS event , satisfy definition American College Cardiology Foundation American Heart Association.37 , 39 A stroke define abrupt-onset , non-convulsive , focal , global neurological deficit last 24 hour , cause ischemia hemorrhage brain.39 Secondary endpoint rate device-oriented outcome include TLR/TVR stent thrombosis 24 month , minor gastrointestinal ( GI ) complication relate cost-effectiveness . TLR define repeat revascularization procedure original lesion index procedure time follow-up period.40 TVR define repeat revascularization procedure involve least one target vessel treat index procedure.40 Stent thrombosis define accord ARC.41 , 42 Minor GI complication assess basis newly develop GI symptom , newly add GI medication , symptom-driven GI endoscopy . At visit , clinician question patient regard GI symptom intermittent epigastric soreness bloat due melena/hematochezia . Any additional GI medication , include H2-blockers proton pump inhibitor , document patient . If patient undergoes endoscopy , type endoscopy , test result , intervention record . Additional medical cost relate minor GI complication ( South Korean won/year ) calculate assess cost effectiveness drug base average Korean expense . All endpoint assess primarily investigator adjudicate secondarily independent clinical event committee .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Male female age ≥20 year 2 . Maintenance dual triple antiplatelet therapy least 12 ± 6 month PCI DES 3 . No history clinical event PCI DES 4 . Plan change antiplatelet monotherapy 5 . Agreement give write informed consent 1 . History hypersensitivity aspirin clopidogrel 2 . History contraindication aspirin clopidogrel 3 . Active pathologic bleeding , peptic ulcer , tumor bleed intracranial hemorrhage 4 . History major bleeding , BARC class ≥3 , result stop antiplatelet agent within 3 month 5 . Bleeding diathesis 6 . Known coagulopathy refusal blood transfusion 7 . Presence noncardiac comorbidity life expectancy &amp; lt ; 2 year randomization 8 . Plan surgery intervention need stop antiplatelet agent ≥3 month 9 . Females childbearing potential breastfeeding 10 . Conditions may result protocol noncompliance committee 11 . Coadministration contraindicate medication follow : P2Y 12 inhibitor ( prasugrel ticagrelor ) ; anticoagulant ( warfarin , new oral anticoagulant , chronic therapy heparin ) ; cytochrome P450 2C19 inhibitor ( fluoxetine , moclobemid voriconazole ) ; probenecid ; high dose methotrexate ( ≥15 mg/week ) ; lithium 12 . Refusal give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Antiplatelet monotherapy</keyword>
	<keyword>Drug-eluting stent</keyword>
</DOC>